Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by Healthcare of Ontario Pension Plan Trust Fund

Posted by Defense World Staff on Feb 26th, 2023

Healthcare of Ontario Pension Plan Trust Fund grew its stake in Royalty Pharma plc (NASDAQ:RPRX – Get Rating) by 8,266.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 48,525 shares of the biopharmaceutical company’s stock after acquiring an additional 47,945 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Royalty Pharma were worth $1,950,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in RPRX. Hsbc Holdings PLC boosted its position in Royalty Pharma by 99.4% during the third quarter. Hsbc Holdings PLC now owns 466,526 shares of the biopharmaceutical company’s stock worth $18,885,000 after acquiring an additional 232,534 shares during the last quarter. Pictet Asset Management SA grew its position in shares of Royalty Pharma by 65.3% in the third quarter. Pictet Asset Management SA now owns 191,256 shares of the biopharmaceutical company’s stock valued at $7,685,000 after purchasing an additional 75,538 shares during the period. Envestnet Asset Management Inc. grew its position in shares of Royalty Pharma by 23.4% in the third quarter. Envestnet Asset Management Inc. now owns 12,498 shares of the biopharmaceutical company’s stock valued at $502,000 after purchasing an additional 2,371 shares during the period. Ontario Teachers Pension Plan Board increased its stake in Royalty Pharma by 44.8% in the third quarter. Ontario Teachers Pension Plan Board now owns 38,150 shares of the biopharmaceutical company’s stock valued at $1,533,000 after purchasing an additional 11,806 shares during the last quarter. Finally, Credit Suisse AG lifted its position in Royalty Pharma by 4.0% during the third quarter. Credit Suisse AG now owns 414,398 shares of the biopharmaceutical company’s stock worth $16,650,000 after buying an additional 15,788 shares during the period. Institutional investors and hedge funds own 55.36% of the company’s stock.

Insider Activity at Royalty Pharma

In other Royalty Pharma news, Director Mario Germano Giuliani sold 165,000 shares of the stock in a transaction that occurred on Thursday, December 1st. The shares were sold at an average price of $44.10, for a total value of $7,276,500.00. Following the completion of the sale, the director now owns 22,225,000 shares of the company’s stock, valued at $980,122,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Rory B. Riggs sold 40,010 shares of the business’s stock in a transaction dated Monday, December 12th. The stock was sold at an average price of $41.98, for a total value of $1,679,619.80. Following the transaction, the director now owns 96,712 shares in the company, valued at $4,059,969.76. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Mario Germano Giuliani sold 165,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 1st. The shares were sold at an average price of $44.10, for a total value of $7,276,500.00. Following the sale, the director now owns 22,225,000 shares of the company’s stock, valued at approximately $980,122,500. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 332,635 shares of company stock worth $14,305,051. 24.86% of the stock is currently owned by company insiders.

Royalty Pharma Price Performance

Royalty Pharma stock opened at $36.38 on Friday. The firm has a fifty day moving average of $38.64 and a 200-day moving average of $41.00. Royalty Pharma plc has a 52-week low of $36.08 and a 52-week high of $44.75. The company has a quick ratio of 2.19, a current ratio of 2.19 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $22.09 billion, a P/E ratio of 454.75, a PEG ratio of 0.79 and a beta of 0.39.

Royalty Pharma Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 15th. Stockholders of record on Thursday, February 16th will be paid a $0.20 dividend. The ex-dividend date is Wednesday, February 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 2.20%. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.19. Royalty Pharma’s dividend payout ratio (DPR) is 1,000.00%.

Analyst Upgrades and Downgrades

RPRX has been the subject of a number of research analyst reports. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, February 16th. TheStreet downgraded shares of Royalty Pharma from a “c-” rating to a “d+” rating in a research note on Tuesday. Morgan Stanley decreased their price target on shares of Royalty Pharma from $54.00 to $51.00 and set an “overweight” rating on the stock in a report on Tuesday, December 6th. Finally, UBS Group dropped their price objective on Royalty Pharma from $51.00 to $48.00 and set a “buy” rating for the company in a report on Thursday, February 16th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Royalty Pharma currently has an average rating of “Buy” and an average target price of $53.86.

Royalty Pharma Company Profile

(Get Rating)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.